Midazolam sedation following open heart surgery

Area of Science:

• Pharmacology
• Anesthesiology
• Critical Care Medicine

Background:

• Postoperative sedation is crucial for patients recovering from cardiopulmonary bypass.
• Midazolam is a commonly used sedative agent.
• Optimizing midazolam administration can improve patient outcomes and resource utilization.

Purpose of the Study:

• To compare the pharmacokinetic profiles of midazolam administered via continuous infusion versus intermittent injections for postoperative sedation.
• To determine the time to achieve stable plasma concentrations and the duration of drug effect after discontinuation.

Main Methods:

• A comparative study involving patients undergoing cardiopulmonary bypass.
• Administration of midazolam via hourly intermittent injections versus continuous infusion at the same dosage.
• Monitoring of plasma midazolam concentrations over time.

Main Results:

• Continuous infusion rapidly achieved stable midazolam plasma concentrations.
• Intermittent injections required 6-8 hours to reach stable trough concentrations.
• Plasma concentrations declined rapidly within 6 hours after stopping infusion.
• One patient exhibited high concentrations and a prolonged half-life, suggesting slow metabolism.

Conclusions:

• Continuous infusion of midazolam is more efficient for achieving rapid and stable plasma concentrations in postoperative sedation.
• Intermittent injections lead to delayed achievement of therapeutic levels.
• Further investigation into genetic factors influencing midazolam metabolism may be warranted.